Logo

Celltrion's Bevacizumab Biosimilar (CT-P16) Enters into Global Phase III Clinical trial for Treating Colorectal Cancer

Share this
Celltrion's Bevacizumab Biosimilar (CT-P16) Enters into Global Phase III Clinical trial for Treating Colorectal Cancer

Celltrion's Bevacizumab Biosimilar (CT-P16) Enters into Global Phase III Clinical trial for Treating Colorectal Cancer

 

Shots: 

 

   • Celltrion has completed Phase I on safety and efficacy of CT-P16 in June 18 

   • CT-P16 extended to Phase III as planned by submission of application to National Authority of Medicines and Health Products- I.P. (Infarmed) of Portugal 

  • Celltrion has plan to conduct Phase III clinical trial for CT-P16 in about 150 sites with 20 countries starting with Portugal- Europe- Asia and South America

 

/ | Ref: Celltrion  | Image: Forbes

 


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions